Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus

E. Tacconelli, M. A. Cataldo, A. Albanese, M. Tumbarello, E. Arduini, T. Spanu, G. Fadda, C. Anile, G. Maira, G. Federico, R. Cauda

Research output: Contribution to journalArticle

Abstract

International guidelines suggest that a high prevalence of meticillin-resistant Staphylococcus aureus (MRSA) infections should influence the use of vancomycin for surgical prophylaxis. In order to compare the efficacy and adverse effects of vancomycin versus cefazolin as antimicrobial prophylaxis for insertion of cerebrospinal fluid (CSF) shunts, a randomised prospective clinical trial was performed. Over a 16-month period, all consecutive adult patients who underwent CSF shunt insertion at a university hospital with a high prevalence of MRSA infections were included. Patients were randomly allocated to receive either vancomycin or cefazolin before surgery and followed-up for four weeks for the development of infections. Of the 176 patients included in the study, 88 received vancomycin and 88 cefazolin. Shunt infections were significantly less likely to be observed in patients who were on vancomycin prophylaxis (4% vs 14%; P = 0.03). All isolated staphylococci were resistant to meticillin. Mortality of patients with post-surgical infections was higher in the cefazolin group (P = 0.02). Our data suggest that use of vancomycin as prophylactic agent for cerebrospinal shunt placement reduces the rate of shunt infections in the context of high prevalence of MRSA.

Original languageEnglish
Pages (from-to)337-344
Number of pages8
JournalJournal of Hospital Infection
Volume69
Issue number4
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Cefazolin
Methicillin
Vancomycin
Staphylococcus aureus
Infection
Cerebrospinal Fluid Shunts
Staphylococcus
Randomized Controlled Trials
Guidelines
Mortality

Keywords

  • Antimicrobial prophylaxis
  • Cefazolin
  • Cerebrospinal fluid shunts
  • Meticillin-resistant Staphylococcus aureus
  • Randomised clinical trial
  • Vancomycin

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus. / Tacconelli, E.; Cataldo, M. A.; Albanese, A.; Tumbarello, M.; Arduini, E.; Spanu, T.; Fadda, G.; Anile, C.; Maira, G.; Federico, G.; Cauda, R.

In: Journal of Hospital Infection, Vol. 69, No. 4, 08.2008, p. 337-344.

Research output: Contribution to journalArticle

Tacconelli, E. ; Cataldo, M. A. ; Albanese, A. ; Tumbarello, M. ; Arduini, E. ; Spanu, T. ; Fadda, G. ; Anile, C. ; Maira, G. ; Federico, G. ; Cauda, R. / Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus. In: Journal of Hospital Infection. 2008 ; Vol. 69, No. 4. pp. 337-344.
@article{ec0b65b9b7ed4f6cb77aa4d5d673f791,
title = "Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus",
abstract = "International guidelines suggest that a high prevalence of meticillin-resistant Staphylococcus aureus (MRSA) infections should influence the use of vancomycin for surgical prophylaxis. In order to compare the efficacy and adverse effects of vancomycin versus cefazolin as antimicrobial prophylaxis for insertion of cerebrospinal fluid (CSF) shunts, a randomised prospective clinical trial was performed. Over a 16-month period, all consecutive adult patients who underwent CSF shunt insertion at a university hospital with a high prevalence of MRSA infections were included. Patients were randomly allocated to receive either vancomycin or cefazolin before surgery and followed-up for four weeks for the development of infections. Of the 176 patients included in the study, 88 received vancomycin and 88 cefazolin. Shunt infections were significantly less likely to be observed in patients who were on vancomycin prophylaxis (4{\%} vs 14{\%}; P = 0.03). All isolated staphylococci were resistant to meticillin. Mortality of patients with post-surgical infections was higher in the cefazolin group (P = 0.02). Our data suggest that use of vancomycin as prophylactic agent for cerebrospinal shunt placement reduces the rate of shunt infections in the context of high prevalence of MRSA.",
keywords = "Antimicrobial prophylaxis, Cefazolin, Cerebrospinal fluid shunts, Meticillin-resistant Staphylococcus aureus, Randomised clinical trial, Vancomycin",
author = "E. Tacconelli and Cataldo, {M. A.} and A. Albanese and M. Tumbarello and E. Arduini and T. Spanu and G. Fadda and C. Anile and G. Maira and G. Federico and R. Cauda",
year = "2008",
month = "8",
doi = "10.1016/j.jhin.2008.04.032",
language = "English",
volume = "69",
pages = "337--344",
journal = "Journal of Hospital Infection",
issn = "0195-6701",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus

AU - Tacconelli, E.

AU - Cataldo, M. A.

AU - Albanese, A.

AU - Tumbarello, M.

AU - Arduini, E.

AU - Spanu, T.

AU - Fadda, G.

AU - Anile, C.

AU - Maira, G.

AU - Federico, G.

AU - Cauda, R.

PY - 2008/8

Y1 - 2008/8

N2 - International guidelines suggest that a high prevalence of meticillin-resistant Staphylococcus aureus (MRSA) infections should influence the use of vancomycin for surgical prophylaxis. In order to compare the efficacy and adverse effects of vancomycin versus cefazolin as antimicrobial prophylaxis for insertion of cerebrospinal fluid (CSF) shunts, a randomised prospective clinical trial was performed. Over a 16-month period, all consecutive adult patients who underwent CSF shunt insertion at a university hospital with a high prevalence of MRSA infections were included. Patients were randomly allocated to receive either vancomycin or cefazolin before surgery and followed-up for four weeks for the development of infections. Of the 176 patients included in the study, 88 received vancomycin and 88 cefazolin. Shunt infections were significantly less likely to be observed in patients who were on vancomycin prophylaxis (4% vs 14%; P = 0.03). All isolated staphylococci were resistant to meticillin. Mortality of patients with post-surgical infections was higher in the cefazolin group (P = 0.02). Our data suggest that use of vancomycin as prophylactic agent for cerebrospinal shunt placement reduces the rate of shunt infections in the context of high prevalence of MRSA.

AB - International guidelines suggest that a high prevalence of meticillin-resistant Staphylococcus aureus (MRSA) infections should influence the use of vancomycin for surgical prophylaxis. In order to compare the efficacy and adverse effects of vancomycin versus cefazolin as antimicrobial prophylaxis for insertion of cerebrospinal fluid (CSF) shunts, a randomised prospective clinical trial was performed. Over a 16-month period, all consecutive adult patients who underwent CSF shunt insertion at a university hospital with a high prevalence of MRSA infections were included. Patients were randomly allocated to receive either vancomycin or cefazolin before surgery and followed-up for four weeks for the development of infections. Of the 176 patients included in the study, 88 received vancomycin and 88 cefazolin. Shunt infections were significantly less likely to be observed in patients who were on vancomycin prophylaxis (4% vs 14%; P = 0.03). All isolated staphylococci were resistant to meticillin. Mortality of patients with post-surgical infections was higher in the cefazolin group (P = 0.02). Our data suggest that use of vancomycin as prophylactic agent for cerebrospinal shunt placement reduces the rate of shunt infections in the context of high prevalence of MRSA.

KW - Antimicrobial prophylaxis

KW - Cefazolin

KW - Cerebrospinal fluid shunts

KW - Meticillin-resistant Staphylococcus aureus

KW - Randomised clinical trial

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=47749130370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749130370&partnerID=8YFLogxK

U2 - 10.1016/j.jhin.2008.04.032

DO - 10.1016/j.jhin.2008.04.032

M3 - Article

C2 - 18602187

AN - SCOPUS:47749130370

VL - 69

SP - 337

EP - 344

JO - Journal of Hospital Infection

JF - Journal of Hospital Infection

SN - 0195-6701

IS - 4

ER -